|

Subcutaneous C1 inhibitor for the long-term prophylaxis of hereditary angioedema -a real life experience.

Baynova, K; Cimbollek, S; Quiralte, J; García, R; Lucena, J M; Lasa Luaces, E; Lara Jiménez, M A; Alvarez Nieto, J; Moreto, J; González-Quevedo, T.

J Investig Allergol Clin Immunol ; : 0, 2023 Oct 04.

Article En | MEDLINE | ID: mdl-37796634

A Review of the Latest Recommendations on the Management of Chronic Urticaria: A Multidisciplinary Consensus Statement from Andalusia, Spain. / Revisión de las últimas novedades en el manejo del paciente con urticaria crónica: Consenso multidisciplinar de la comunidad autónoma de Andalucía.

Alcántara Villar, M; Armario Hita, J C; Cimbollek, S; Fernández Ballesteros, M D; Galán Gutiérrez, M; Hernández Montoya, C; Lara-Jiménez, M Á; Pereyra Rodríguez, J J; Vega Chicote, J M; Ruiz-Villaverde, R.

Actas Dermosifiliogr (Engl Ed) ; 111(3): 222-228, 2020 Apr.

Article En, Es | MEDLINE | ID: mdl-31983389

Chronic urticaria is a difficult-to-treat skin disorder that has a major impact on patient quality of life. The latest update of the European guideline on the management of urticaria was published in 2018. In this consensus statement, produced in the autonomous community of Andalusia, Spain, we describe a multidisciplinary approach for applying the new treatment algorithm proposed by the European guideline in our region.

Chronic Urticaria , Urticaria , Consensus , Humans , Quality of Life , Spain , Urticaria/diagnosis

Omalizumab for the treatment of chronic spontaneous urticaria in daily clinical practice in South Spain.

Ruiz-Villaverde, R; Pereyra-Rodriguez, J J; Hernández-Montoya, C; Galán-Gutierrez, M; Alcantara-Luna, S; Lara-Jimenez, M A.

Dermatol Ther ; 31(5): e12669, 2018 09.

Article En | MEDLINE | ID: mdl-30063807

Anti-Allergic Agents/therapeutic use , Omalizumab/therapeutic use , Urticaria/drug therapy , Chronic Disease , Female , Humans , Male , Quality of Life , Severity of Illness Index , Spain

Angioedema adquirido por déficit de C1 inhibidor secundario a linfoma B esplénico de la zona marginal / Acquired angioedema with C1 inhibitor deficiency secondary to splenic marginal zone B-cell lymphoma

Lara-Jiménez, M. A; Ruiz-Rivera, L; Magro-Checa, C.

Rev. clín. esp. (Ed. impr.) ; 214(9): e107-e109, dic. 2014. ilus

Article Es | IBECS | ID: ibc-130214

No disponible

Humans , Female , Middle Aged , Angioedema/complications , Angioedema/diagnosis , Lymphoma, B-Cell/complications , Lymphoma, B-Cell/diagnosis , Edema/diagnosis , Adrenal Cortex Hormones/therapeutic use , Histamine Antagonists/therapeutic use , Danazol/therapeutic use , Splenomegaly/complications , Splenomegaly/diagnosis , Asthenia/complications , Anorexia/complications , Weight Loss , Sweating , Tomography, Emission-Computed/methods , Tomography, Emission-Computed/trends

Acquired angioedema with C1 inhibitor deficiency secondary to splenic marginal zone B-cell lymphoma. / Angioedema adquirido por déficit de C1 inhibidor secundario a linfoma B esplénico de la zona marginal.

Lara-Jiménez, M A; Ruiz-Rivera, L; Magro-Checa, C.

Rev Clin Esp (Barc) ; 214(9): e107-9, 2014 Dec.

Article En, Es | MEDLINE | ID: mdl-24970460

Dabigatran para el tratamiento de una paciente con obesidad mórbida y trombosis venosa recidivante / Dabigatran in the treatment of amorbidly obese patient with recurring venous

Callejas Rubio, J. L; Lara Jiménez, M. A; Fernández Pugnaire, M. A; Ortego Centeno, N.

Farm. hosp ; 34(2): 101-101, mar.-abr. 2010.

Article Es | IBECS | ID: ibc-105365

Humans , Female , Middle Aged , Obesity, Morbid/complications , Venous Thrombosis/prevention & control , Fibrinolytic Agents/administration & dosage , Risk Factors

[Dabigatran in the treatment of a morbidly obese patient with recurring venous thrombosis]. / Dabigatran para el tratamiento de una paciente con obesidad mórbida y trombosis venosa recidivante.

Callejas Rubio, J L; Lara Jiménez, M A; Fernández Pugnaire, M A; Ortego Centeno, N.

Farm Hosp ; 34(2): 101, 2010.

Article Es | MEDLINE | ID: mdl-20304372

Anticoagulants/therapeutic use , Benzimidazoles/therapeutic use , Obesity, Morbid/complications , Pyridines/therapeutic use , Venous Thrombosis/drug therapy , Acenocoumarol/adverse effects , Acenocoumarol/therapeutic use , Anticoagulants/adverse effects , Compassionate Use Trials , Dabigatran , Female , Hematoma/chemically induced , Heparin, Low-Molecular-Weight/adverse effects , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Middle Aged , Recurrence , Thrombophilia/drug therapy , Thrombophilia/etiology , Venous Thrombosis/etiology

Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome.

Sánchez-Cano, D; Callejas-Rubio, J L; Lara-Jiménez, M A; López-Trascasa, M; Circadi, M; Ortego-Centeno, N.

Lupus ; 17(3): 228-9, 2008 Mar.

Article En | MEDLINE | ID: mdl-18372365

Antibodies, Monoclonal/therapeutic use , Complement C1 Inhibitor Protein/analysis , Sjogren's Syndrome/complications , Aged , Angioedema/etiology , Antibodies, Monoclonal, Murine-Derived , Complement C1 Inhibitor Protein/physiology , Female , Humans , Rituximab